Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Neurol Sci. 2021 May;42(Suppl 1):9-13. doi: 10.1007/s10072-021-05270-7. Epub 2021 Apr 27.
Approximately 3-10% of patients with multiple sclerosis (MS) have onset during childhood. Pediatric MS is characterized by a relapsing-remitting course and a high relapse rate. In 2010, fingolimod (Gilenya®) was approved in the USA for the treatment of relapsing-remitting MS in adults. In 2018, both the United States Food and Drug Administration and the European Medicines Agency expanded the approved indications of fingolimod to include its use in children with relapsing MS, and the drug was approved in Italy for this indication in September 2020. We describe two cases of children with relapsing-remitting MS who were treated with fingolimod at IRCCS Ospedale San Raffaele Multiple Sclerosis Center (Milan, Italy) for more than 2 years. Our real-world data confirm that fingolimod is an effective therapeutic strategy for children with relapsing MS, and its use could be considered in pediatric patients with active disease.
约 3-10%的多发性硬化症（MS）患者在儿童时期发病。儿科 MS 的特征是复发缓解病程和高复发率。2010 年，芬戈莫德（Gilenya®）在美国获得批准，用于治疗成人复发缓解型 MS。2018 年，美国食品和药物管理局和欧洲药品管理局扩大了芬戈莫德的批准适应证，将其用于复发型 MS 儿童，该药于 2020 年 9 月在意大利获得该适应证批准。我们描述了在意大利米兰圣拉斐尔多发性硬化症中心（IRCCS Ospedale San Raffaele）接受芬戈莫德治疗超过 2 年的 2 例复发缓解型 MS 儿童的病例。我们的真实世界数据证实，芬戈莫德是治疗复发型 MS 儿童的有效治疗策略，可考虑在活动期儿科患者中使用。
